New Vessel Formation and Aberrant VEGF/VEGFR Signaling in Acute Leukemia: Does it Matter?

  title={New Vessel Formation and Aberrant VEGF/VEGFR Signaling in Acute Leukemia: Does it Matter?},
  author={Eveline S J M de Bont and Veronica Neefjes and Stefano Rosati and Edo Vellenga and W A Kamps},
  journal={Leukemia \& Lymphoma},
  pages={1901 - 1909}
Although many patients with acute leukemia achieve a hematological complete remission with aggressive intensive therapy protocols, a large proportion shows reoccurrence of disease. Novel strategies are warranted. In acute leukemia new vessel formation is observed. New vessel formation is the result of angiogenesis and vasculogenesis. The degree of neovascularization in the bone marrow is correlated with vascular endothelial growth factor (VEGF) expression in the leukemic cells. The present… 

Role of VEGF/VEGFR in the pathogenesis of leukemias and as treatment targets (Review).

Recent advances in understanding the role of VEGF and its receptors as attractive targets for therapies are summarized and a promising therapeutic intervention in multiple types of hematolymphoid tumors is demonstrated.

Bone marrow VEGFC expression is associated with multilineage dysplasia and several prognostic markers in adult acute myeloid leukemia, but not with survival

VEGFC expression was increased in AML patients with myelodysplasia-related changes and in subgroups with a poorer prognosis, but has no impact on survival.

Vascular endothelial growth factor C—a potent risk factor in childhood acute lymphoblastic leukaemia: an immunocytochemical approach

To investigate the immunocytochemical expression of vascular endothelial growth factor C and its receptors in childhood acute lymphoblastic leukaemia blasts and to determine the possible role of this complex in the pathogenesis and prognosis of ALL.

Angiogenesis and the role of bone marrow endothelial cells in haematological malignancies.

There is a need for additional methods that allow the estimation of ongoing angiogenesis in patients with multiple myeloma, and double immunostainings for CD34 and Ki-67 can be used on paraffin-embedded tissue to determine the endothelial proliferation fraction.

Selected Aspects of Angiogensis in Haematological Malignancies

There is a strong need for further investigations in this area, since antiangiogenic therapy is a potential adjunct to conventional therapy of lymphoproliferative disorders.

Oncogene and non-oncogene addiction in inflammation-associated cancers.

A solid understanding of oncogene and non-oncogene addiction in cancer-associated inflammatory microenvironments will help to exploit cancer drug targets for cancer prevention and clinical treatment.

Alterations of the bone marrow stromal microenvironment in adult patients with acute myeloid and lymphoblastic leukemias before and after allogeneic hematopoietic stem cell transplantation

Allo-HSCT conditioning regimens significantly damaged MMSCs and CFU-Fs, and the effect lasted for at least 1 year, but gene expression levels were altered.

Vandetanib mediates anti-leukemia activity by multiple mechanisms and interacts synergistically with DNA damaging agents

Preclinical data support clinical evaluation of vandetanib, in combination with cytotoxic chemotherapy, for pediatric leukemia as a potential therapeutic strategy for patients with relapsed/refractory acute leukemia.

Effect of Hypoxia on Transforming Growth Factor-beta Signaling Pathway in Osteoarthritic Human Cartilage

Objective: Due to avascularity, chondrocytes have poor ability to regenerate themselves which is challanging for tissue engineering to achieve full functioning cartilage. Culturing chondrocytes or



Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia.

The results suggest that at least in AML patients with higher WBC and blast counts, cellular VEGF level is an independent predictor of outcome.

Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes.

The data suggest that vascularity and angiogenic factors are increased in leukemias and MDS and may play a role in theLeukemogenic process.

Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia.

There is evidence of increased microvessel density in the bone marrow of patients with AML, which supports the hypothesis of an important role of angiogenesis in AML and suggests that antiangiogenic therapy might constitute a novel strategy for the treatment of AML.

Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies.

The results raise the possibility that VEGF may play a role in the growth of hematopoietic neoplasms such as multiple myeloma through either a paracrine or an autocrine mechanism.

Increased bone marrow vascularization in patients with acute myeloid leukaemia: a possible role for vascular endothelial growth factor

The results suggest that malignant cell proliferation, angiogenesis and VEGF expression are linked in AML and might contribute to the growth advantage of the malignant counterpart as a result of the paracrine production of growth factors produced by the surrounding endothelial cells.

Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration.

It is demonstrated that certain leukemias not only produce VEGF but also express functional VEGFR-2 in vivo and in vitro, resulting in the generation of an autocrine loop that may support leukemic cell survival and proliferation.

Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia.

Investigation of expression of VEGF and its receptors on fresh leukemic blasts of AML blasts found a dose-dependent increase of granulocyte-macrophage colony-stimulating factor secretion from endothelial cells was identified.

VEGF-C signaling pathways through VEGFR-2 and VEGFR-3 in vasculoangiogenesis and hematopoiesis.

Results demonstrate that elaborated control through VEG FR-3 signaling is critical in vasculoangiogenesis and hematopoiesis, and the binding of VEGF-C to VEGFR-3 consequently regulates VEGfr-2 signaling.

Vascular endothelial growth factor secretion is an independent prognostic factor for relapse-free survival in pediatric acute myeloid leukemia patients.

Within the limits of the small patient population, VEGF levels as well as age at diagnosis had an independent significant effect on relapse-free survival and the influence of different variables on therapeutic outcome was analyzed.

Clinical relevance of intracellular vascular endothelial growth factor levels in B-cell chronic lymphocytic leukemia.

For the entire group of patients, no correlation was found between VEGF levels and beta2-M levels or Rai and Binet stage, but in a subgroup of CLL patients with good prognoses or early-stage disease, lower levels of V EGF were associated with shorter survival times.